Boehringer Ingelheim Pharma
Boehringer Ingelheim Pharma is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
Sponsor Scleroderma Research Foundation
- Start (EU)
- Latest update
- Estimated end
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants – a multicentre randomised placebo-controlled clinical trial
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Latest update
- Estimated end
- Not reported
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC)
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
EASi-HF Preserved – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Boehringer Ingelheim Pharma?
The 2026-10-09 snapshot links Boehringer Ingelheim Pharma to 4 distinct CTIS trials. Recorded services include Biobanking Biopsy, Laboratory services, Medicinal product management, Other - Biobanking DNA. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Boehringer Ingelheim Pharma?
The most frequently recorded therapeutic areas are Gastroenterology, Immunology, Neurology, Respiratory. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Boehringer Ingelheim Pharma conducted?
The linked trials record locations in 16 countries, including Germany, Belgium, Spain, Italy, France. These are trial locations, not confirmed office locations or countries where Boehringer Ingelheim Pharma delivered services.
What can this page tell me about Boehringer Ingelheim Pharma's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Boehringer Ingelheim Pharma. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Boehringer Ingelheim Pharma GmbH & Co. KG